ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Stock-Based Compensation history
Currency unavailable · from the cash flow
No Stock-Based Compensation data reported for this period type.
Stock-Based Compensation vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.93M USD | +107.3% | -8.3% | 60.1% | |
| LTM Mar 2026 | $28.23M USD | +6.4% | +65.5% | 699.8% | |
| LTM Mar 2026 | $26.2M USD | -9.4% | +12.2% | 81.7% | |
| LTM Mar 2026 | $23.07M USD | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $21.73M USD | +42.8% | — | 30.3% | |
| LTM Mar 2026 | $14.34M USD | — | -14.0% | 1556.3% | |
| LTM Mar 2026 | $12.56M USD | +183.6% | +171.6% | — | |
| FY2025 | $7.68M USD | — | — | 41.2% | |
| LTM Mar 2026 | €2.03M EUR | -21.0% | — | 15.1% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +6.4% | +3.1% | 55.5% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.